Prime Medicine Past Earnings Performance
Past criteria checks 0/6
Prime Medicine's earnings have been declining at an average annual rate of -29.2%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 54.6% per year.
Key information
-29.2%
Earnings growth rate
28.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -54.6% |
| Return on equity | -115.7% |
| Net Margin | -27,406.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Prime Medicine's Promising Pipeline: PM359 And Cash Burn Concerns
Sep 04Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation
Sep 04
Prime Medicine Stock: Only For The Most Patient Of Investors
Jun 20Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
May 14Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing
Jan 28Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Aug 25We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Rate
May 12Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?
Jan 24Revenue & Expenses Breakdown
How Prime Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -219 | 51 | 0 |
| 30 Jun 24 | 1 | -217 | 47 | 0 |
| 31 Mar 24 | 1 | -204 | 45 | 0 |
| 31 Dec 23 | 0 | -198 | 43 | 0 |
| 30 Sep 23 | 0 | -173 | 40 | 0 |
| 30 Jun 23 | 0 | -158 | 36 | 0 |
| 31 Mar 23 | 0 | -151 | 33 | 0 |
| 31 Dec 22 | 0 | -142 | 30 | 0 |
| 30 Sep 22 | 0 | -171 | 27 | 0 |
| 30 Jun 22 | 0 | -158 | 24 | -10 |
| 31 Mar 22 | 0 | -126 | 19 | 0 |
| 31 Dec 21 | 0 | -184 | 14 | 0 |
| 30 Sep 21 | 0 | -118 | 8 | 0 |
| 31 Dec 20 | 5 | -5 | 3 | 0 |
Quality Earnings: PRME is currently unprofitable.
Growing Profit Margin: PRME is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRME is unprofitable, and losses have increased over the past 5 years at a rate of 29.2% per year.
Accelerating Growth: Unable to compare PRME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PRME has a negative Return on Equity (-115.7%), as it is currently unprofitable.